Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

Study Questions:

What is the safety and efficacy of combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II-receptor blocker (ARB), as compared with ARB monotherapy, in slowing the progression of proteinuric diabetic nephropathy?